window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 19, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

MHRA

  • Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Research & Development

    Tenpoint submits UK application for presbyopia eye drop YUVEZZI

    Tenpoint Therapeutics has submitted a Marketing Authorization Application (MAA) to [...]

    July 14, 2026
  • Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Healome raises £2M to advance eye-drop technology for ocular surface diseases

    Healome Therapeutics has raised £2 million in seed funding to [...]

    July 8, 2026
  • Clinical & Regulatory,Manufacturing & Supply Chain

    Reacta expands MHRA licence to bring analytical testing in-house

    reacta-mhra-licence-analytical-testing Reacta Healthcare has received an extension to its Manufacturer’s [...]

    June 10, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE backs AQUIPTA for acute migraine treatment in England and Wales

    The National Institute for Health and Care Excellence (NICE) has [...]

    June 9, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE backs serplulimab for extensive-stage small cell lung cancer

    People with extensive-stage small cell lung cancer in England and [...]

    June 6, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Quotient Sciences begins Phase 1 study of AI-designed drug formulation

    Quotient Sciences has begun a Phase 1 clinical study evaluating [...]

    June 6, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Opinion & Events,Pharmaceuticals and therapeutics

    Bristol Myers Squibb to launch Cobenfy in the UK at US list price for adults with schizophrenia

    Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Servier receives UK marketing authorisation for vorasidenib for low grade glioma

    Servier has received marketing authorisation from the Medicines and Healthcare [...]

    May 5, 2026
  • Medical devices

    Morphic Medical appoints Jane Wright as chief financial officer during European rollout of Reset

    Appointment strengthens leadership team as company expands access to its [...]

    September 15, 2025
  • Clinical & Regulatory,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    Symbiosis expands quality leadership with new qualified person appointment

    Symbiosis Pharmaceutical Services has appointed Wendy Cook as a qualified [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • CN Bio wins Innovate UK grant to develop human-relevant drug testing workflow
    Categories: Digital & Data, Drug Discovery & Development, Manufacturing & Supply Chain, Research & Development
  • FDA grants Priority Review to Belite Bio’s tinlarebant for Stargardt disease
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Skylark Bio doses first patient in Phase 1/2 trial for GJB2-related deafness
    Categories: Advanced Therapies, Clinical & Regulatory, Genomics and sequencing, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top